MDXG - MiMedx Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.10
+0.23 (+2.12%)
At close: 1:00PM EST
Stock chart is not supported by your current browser
Previous Close10.87
Open10.89
Bid10.60 x 100
Ask11.43 x 2100
Day's Range10.72 - 11.15
52 Week Range7.64 - 17.47
Volume635,840
Avg. Volume3,031,050
Market Cap1.232B
Beta0.42
PE Ratio (TTM)58.42
EPS (TTM)0.19
Earnings DateOct 25, 2017 - Oct 30, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • Capital Cube13 hours ago

    ETFs with exposure to MiMedx Group, Inc. : November 24, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MiMedx Group, Inc. Here are 5 ETFs with the largest exposure to MDXG-US. Comparing the performance and risk of MiMedx Group, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire3 days ago

    MiMedx to Present at the 29th Annual Piper Jaffray Healthcare Conference

    MARIETTA, Ga. , Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • PR Newswire4 days ago

    MiMedx Provides Update On Its Reimbursement Coverage

    MARIETTA, Ga., Nov. 21, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, provided a reimbursement update today. Parker H. "Pete" Petit, Chairman and Chief Executive Officer, said "With the publication of the Venous Leg Ulcer (VLU) study earlier this quarter, one of the nation's largest not-for-profit health plans serving more than 3 million people recently decided to add EpiFix® coverage for Diabetic Foot Ulcers (DFUs), VLUs and burns. The Company also provided a reimbursement update in light of the recently issued Food and Drug Administration (FDA) Final and Draft Guidance documents related to human tissue titled, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (the "HCT/P Guidance").

  • PR Newswire5 days ago

    MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers

    MARIETTA, Ga. , Nov. 20, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • PR Newswire8 days ago

    MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document

    MARIETTA, Ga., Nov. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Food and Drug Administration (FDA) issued numerous Final and Draft Guidance documents.  Among them was the final Guidance document related to human tissue titled, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" (the "HCT/P Guidance").  Additionally, "Evaluation of Devices Used with Regenerative Medicine Advanced Therapies," Draft Guidance for Industry was published (the "RMAT Guidance"). In the final HCT/P Guidance document, FDA updated and clarified its previous draft Guidance documents regarding HCT/Ps.

  • PR Newswire10 days ago

    MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers

    MARIETTA, Ga., Nov. 14, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short sellers. Parker H. "Pete" Petit, Chairman and CEO, stated, "MiMedx will continue to expose the false allegations and contrived innuendo propagated by these illegal short-sellers, especially those that are associated with the Company's compliance with regulatory requirements.  Their baseless allegations are simply designed to denigrate the Company's reputation in order to reinforce the short-sellers' theme of 'short and distort.'  The business practices and supportive culture of the Company have been well-established for many years, and they are based on honesty and integrity.

  • Capital Cube11 days ago

    ETFs with exposure to MiMedx Group, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MiMedx Group, Inc. Here are 5 ETFs with the largest exposure to MDXG-US. Comparing the performance and risk of MiMedx Group, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • GlobeNewswire16 days ago

    Detailed Research: Economic Perspectives on MiMedx Group, Zoetis, Six Flags Entertainment, Continental Resources, Boardwalk Pipeline Partners, LP, and Western Union – What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MiMedx ...

  • PR Newswire16 days ago

    MiMedx To Webcast Its Investor's Day Conference on November 30, 2017

    MARIETTA, Ga., Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will be hosting and webcasting its Investor's Day Conference on Thursday, November 30, 2017.

  • PR Newswire17 days ago

    MiMedx to Present at Jefferies 2017 London Healthcare Conference

    MARIETTA, Ga. , Nov. 8, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • PR Newswire22 days ago

    MiMedx To Present At The Canaccord|Genuity Medical Technology And Diagnostics Forum

    MARIETTA, Ga. , Nov. 2, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
    Capital Cube23 days ago

    MiMedx Group, Inc. :MDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017

    Categories: Yahoo FinanceGet free summary analysis MiMedx Group, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of MiMedx Group, Inc. – CryoLife, Inc., NuVasive, Inc., STERIS Plc and C. R. Bard, Inc. (CRY-US, NUVA-US, STE-US and BCR-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • PR Newswire24 days ago

    MiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions

    MARIETTA, Ga., Nov. 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that the Company has agreed to a confidential settlement of the lawsuit the Company filed against BioResolutions LLC d/b/a Halo Wound Solutions (Halo) and one of the Halo executives. MiMedx filed its lawsuit against Halo and its executive, Tracy Lucas, in January 2017. In its suit, MiMedx alleged that Lucas used MiMedx trade secrets and other confidential, proprietary business information to unlawfully solicit the sales of Halo's medical products with the assistance of MiMedx employees, and tortiously interfered with MiMedx's contracts with its employees.

  • IBD Rating Upgrades: MiMedx Shows Improved Technical Strength
    Investor's Business Daily25 days ago

    IBD Rating Upgrades: MiMedx Shows Improved Technical Strength

    MiMedx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

  • PR Newswire25 days ago

    MiMedx Group Investor Reminder and Update: Hagens Berman Reminds MiMedx Group Investors of Investigation into Possible Securities Law Violations Related to Report Questioning MiMedx's Accounting Practices and Alerts Them to Recent Claims of Potential Accounting Irregularities

    SAN FRANCISCO , Oct. 30, 2017 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in MiMedx Group, Inc. (NASDAQ: MDXG) of the firm's investigation into possible securities law violations ...

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of MDXG earnings conference call or presentation 27-Oct-17 2:30pm GMT

    Q3 2017 MiMedx Group Inc Earnings Call

  • PR Newswire26 days ago

    MiMedx CEO Replies to Fraudulent Information About The Company

    MARIETTA, Ga. , Oct. 30, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • PR Newswire29 days ago

    MiMedx Exposes Content of a Short Seller Website Dedicated to Posting Defamatory and False Information About The Company

    MARIETTA, Ga. , Oct. 27, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...

  • Stocks With Rising Relative Strength: MiMedx
    Investor's Business Daily29 days ago

    Stocks With Rising Relative Strength: MiMedx

    A Relative Strength Rating upgrade for MiMedx shows improving technical performance. Will it continue?

  • Associated Press29 days ago

    MiMedx posts 3Q profit

    On a per-share basis, the Marietta, Georgia-based company said it had net income of 15 cents. Earnings, adjusted for one-time gains and costs, were 8 cents per share. The developer of biomaterials made ...

  • PR Newswire29 days ago

    MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance

    MIMEDX OPERATING INCOME GROWS 88% ON 31% REVENUE GROWTH RECORD CASH FLOW FROM OPERATIONS OF $18.0 MILLION MARIETTA, Ga. , Oct. 26, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical ...

  • Is MiMedx Group Inc (MDXG) As Financially Strong As Its Balance Sheet Indicates?
    Simply Wall St.last month

    Is MiMedx Group Inc (MDXG) As Financially Strong As Its Balance Sheet Indicates?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like MiMedx Group Inc (NASDAQ:MDXG), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • Business Wirelast month

    Glancy Prongay & Murray LLP Commences Investigation on Behalf of MiMedx Group, Inc. Investors (MDXG)

    Glancy Prongay & Murray LLP announces an investigation on behalf of MiMedx Group, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • Business Wirelast month

    MDXG INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of MiMedx Group, Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of MiMedx Group, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • PR Newswirelast month

    MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Seller Attacks

    MARIETTA, Ga. , Oct. 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental ...